Paul Ehrlich

Paul Ehrlich the German physician and scientist (1854-1915) who pioneered chemotherapy and immunology and developed the first effective treatment for syphilis. His side-chain theory of immunity and his search for chemical substances that would kill pathogens without harming the patient established the principles of modern drug therapy, and his work earned him a Nobel Prize.

Early Life and Education

Paul Ehrlich was born in Strehlen, in the Prussian province of Silesia, into a Jewish family of comfortable means. His father ran a distillery and inn, and the family hoped he would enter medicine. He attended university at Breslau, Strasbourg and Freiburg, and he qualified as a physician in Leipzig with a doctoral thesis on the theory and practice of histological staining.

From the beginning of his career he was fascinated by the chemistry of dyes and their affinity for particular tissues and cells. He observed that certain dyes stained specific structures selectively, and he reasoned that this selectivity must reflect a chemical interaction between the dye and the tissue, an insight that became the foundation of his later work.

He worked in several hospitals and laboratories, including a period at the Charite in Berlin, where he studied haematology and developed methods of staining blood cells that are still used in modified form. His practical innovations in staining made him widely known among pathologists long before his work on immunity.

Immunology and the Side-Chain Theory

Working with Emil von Behring and others, Ehrlich studied the antibodies produced in response to toxins such as diphtheria toxin and tetanus toxin. He helped to develop assays for measuring the strength of antitoxic sera, and he demonstrated that the potency of a serum could be standardised, a crucial step in the production of effective therapeutic sera for diphtheria.

To explain how the body produces specific antibodies he proposed the side-chain theory, according to which cells carry chemical side chains on their surface that can combine with particular foreign substances. Combining with a toxin would stimulate the cell to produce more of these side chains, which were then released into the blood as circulating antibodies.

The theory accounted for the extraordinary specificity of the immune response, and although it was later modified and superseded in its details, it introduced the idea that immunity depends on specific chemical structures and led to the concept of receptors on the surfaces of cells, a central idea in modern biology and pharmacology.

Chemotherapy and the Magic Bullet

Ehrlich's ambition was to find chemical substances that would attach themselves to pathogens and kill them without damaging the tissues of the patient, an idea he expressed in the phrase magic bullet. He reasoned that if a compound could be found with a specific affinity for a parasite, and with a toxic action appropriate to it, it might function as a targeted drug.

He worked initially with dyes, testing whether compounds such as trypan red could cure trypanosome infections, and he made progress in treating sleeping sickness with organic arsenic compounds. He and his chemist colleagues synthesised and tested hundreds of substances, systematically varying their structure and measuring their effect on infected animals, an approach that prefigured modern drug development.

The most famous result was the discovery of compound 606, later named salvarsan, an arsenic-based drug that proved effective against the spirochete that causes syphilis. After careful testing and some refinement to reduce side effects, the compound was introduced for clinical use and became the first widely used synthetic chemotherapeutic agent.

Salvarsan, Controversy and Later Years

Salvarsan transformed the treatment of syphilis, a disease for which no effective drug had existed, and brought Ehrlich worldwide fame. It required careful administration by injection and was not without danger, but the improvement in the prospects of patients was substantial, and it was used for decades until it was replaced by penicillin.

The development of the drug was surrounded by controversy. Ehrlich faced criticism over the patenting and commercialisation of salvarsan, and there were disputes about its side effects and about the methods used to distribute it. He defended his decision to make the remedy widely available while insisting on the need for careful medical supervision.

He shared the Nobel Prize in Physiology or Medicine in 1908 with Ilya Mechnikov for work on immunity, and he founded the institute in Frankfurt that bears his name, where he continued to direct research until his health failed. He died in 1915, and he left a legacy of a scientific institute and a body of work that shaped both immunology and pharmacology.

Influence and Legacy

Ehrlich's vision of chemotherapy, the deliberate chemical attack on pathogens using substances selected for their specificity, became one of the guiding programmes of twentieth-century medicine. The later development of antibiotics and of targeted drugs rests on the principles he established and on the experimental methods he pioneered.

His side-chain theory and his concept of receptors influenced the development of immunology, cell biology and pharmacology, and his insistence on quantitative assay and standard preparation shaped the way drugs and sera are tested and regulated today. He is regarded as a founder of both immunology and chemotherapy.

The institute he founded remains a major centre for medical research, and his name is associated with awards and prizes in immunology. He is remembered as a scientist who combined imaginative speculation with meticulous experimental work, and whose search for targeted remedies anticipated much of modern drug therapy.

See also

• Chemotherapy
• Immunology
• Salvarsan
• Antibody